72922-61-3 Usage
General Description
4-NITRO-6-INDAZOLECARBOXYLIC ACID METHYL ESTER is a chemical compound that belongs to the class of indazole derivatives. It is a methyl ester of 4-nitro-6-indazolecarboxylic acid and is known for its potential biological activities. The compound has been studied for its pharmacological properties, including its anticancer and antimicrobial activities. It has also been investigated for its potential use in drug development, particularly in the synthesis of novel pharmaceutical compounds. The compound's chemical structure and properties make it a valuable candidate for further research and development in the field of medicinal chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 72922-61-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 7,2,9,2 and 2 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 72922-61:
(7*7)+(6*2)+(5*9)+(4*2)+(3*2)+(2*6)+(1*1)=133
133 % 10 = 3
So 72922-61-3 is a valid CAS Registry Number.
InChI:InChI=1/C9H7N3O4/c1-16-9(13)5-2-7-6(4-10-11-7)8(3-5)12(14)15/h2-4H,1H3,(H,10,11)
72922-61-3Relevant articles and documents
Compound with dual inhibitory activity TDO, IDOO1 and application of compound for treating neurodegenerative disease (by machine translation)
-
, (2020/10/06)
The present invention provides a compound of formula I, or a pharmaceutically acceptable salt thereof, or a solvate thereof, which can selectively inhibit TDO, IDOO1, which has a significant inhibitory effect on TDO and/or IDOO1. In addition, the prepared compound has a remarkable anti-tumor effect, has a certain treatment effect on's disease and's disease, and has a good application prospect in the field of medicine preparation. (by machine translation)
HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
-
Page 56, (2010/02/07)
The present invention relates to novel hydroxyethylamine compounds of formula (I): (I) having Asp2 (-secretase, BACE1 or Memapsin) inhibitory activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterised by elevated-amyloid levels or-amyloid deposits, particularly Alzheimer's disease.
